In 2023, we wrote about the Supreme Court’s decision in United States ex. rel. Schutte v. SuperValu Inc. interpreting the False Claims Act’s (FCA) scienter standard to require inquiry into a defendant’s subjective knowledge....more
6/26/2025
/ Breach of Contract ,
Centers for Medicare & Medicaid Services (CMS) ,
Damages ,
Expert Testimony ,
False Claims Act (FCA) ,
Healthcare ,
Healthcare Fraud ,
Jury Trial ,
Liability ,
Litigation Strategies ,
Medicaid ,
Medicare ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Scienter ,
SCOTUS ,
Statutory Interpretation ,
Subjective Standard ,
US ex rel Tracy Schutte et al v SuperValu Inc et al
President Donald Trump has signed more than 60 executive orders since taking office, including Executive Order 14173, titled “Ending Illegal Discrimination and Restoring Merit-Based Opportunity” (EO 14173 or the Executive...more
As we take stock of the Supreme Court’s 2023 term, two landmark decisions shift our understanding of scienter and government intervention as it relates to the False Claims Act (“FCA”), 31 U.S.C. § 3729. First, on June 1,...more
9/15/2023
/ Department of Justice (DOJ) ,
Drug Pricing ,
False Claims Act (FCA) ,
Foreign Corrupt Practices Act (FCPA) ,
Healthcare ,
Medicaid ,
Medicare ,
Prescription Drugs ,
Qui Tam ,
Reasonable Interpretations ,
Scienter ,
SCOTUS ,
United States ex rel Polansky v Executive Health Resources Inc ,
US ex rel Tracy Schutte et al v SuperValu Inc et al
As companies begin planning for the upcoming year, attorneys who sit on promotional review committees should consider the significant guidance published by the U.S. Food and Drug Administration (“FDA”) and update process aids...more